Effects Of Fastigial Nucleus Stimulation On Serum Inflammatory Factors In Patients With Coronary Heart Disease

Objective: To observe the effects of fastigial nucleus stimulation on serum high-sensitivity C-reactive protein(hs-CRP),interleukin-6(IL-6),tumor necrosis factor ?(TNF-?),lipoprotein-associated phospholipase A2(Lp-PLA2)in patients with coronary heart disease.Methods: This study was a prospective randomized controlled trial.A total of 144 patients with coronary heart disease were diagnosed by coronary angiography.The enrolled patients were divided into two groups according to the random number table,namely the control group(n=72)and the experimental group(n=72).According to clinical data,both the two groups were divided into acute coronary syndrome(ACS)subgroup and stable angina pectoris(SA)subgroup.The control group received the best drug treatment;the experimental group also received standardized drug treatment,and at the same time,it was given fastigial nucleus stimulation treatment for about 3 weeks,once a day for 30 minutes each time.General clinical data at the time of admission to both groups were collected.The levels of serum hs-CRP,TNF-?,IL-6 and Lp-PLA2 were measured before and after treatment in both groups.Results: 1.General information: There was no significant difference between the experimental group and the control group in terms of gender,age,body mass index,smoking history,history of hypertension,history of diabetes,total cholesterol,high density lipoprotein,low density lipoprotein,andtriglyceride(P>0.05);in the ACS subgroup and SA subgroup analysis,the above indicators were not significantly different(P>0.05).2.Serum hs-CRP,TNF-?,IL-6 and Lp-PLA2 levels in the experimental group before treatment were:(20.05±11.26)mg/l,(10.08±5.62)pg/ml,(6.65±3.19)pg/ml,(270.58±132.66)ng/ml;serum hs-CRP,TNF-?,IL-6 and Lp-PLA2 levels in the control group were(19.25±10.20)mg/l,(10.11±5.71)pg/ ml,(6.93±3.34)pg/ml,(286.55±135.55)ng/ml.There was no statistical difference in the above indicators between the two groups(P>0.05).In ACS subgroup,before treatment,the serum hs-CRP,TNF-?,IL-6,and Lp-PLA2 levels in the experimental group were:(29.56±7.16)pg/ml,(13.23±5.80)pg/ml,(8.60±3.21)pg/ml,(382.26±126.90)pg/ml;control group serum hs-CRP,TNF-?,IL-6 and Lp-PLA2 levels were(28.66±16.44)pg/ml,(12.97±5.95)pg/ml,(8.96±3.10)pg/ml,(386.63±118.53)pg/ml.There was no significant difference in the above indexes between the two groups(P>0.05).In SA subgroup,before treatment,the serum hs-CRP,TNF-?,IL-6 and Lp-PLA2 levels in the experimental group were:(7.60±1.67)pg/ml,(6.38±2.47)pg/ml,(4.46±1.00)pg/ml,(142.58±21.50)pg/ml;control group serum hs-CRP,TNF-?,IL-6 and Lp-PLA2 levels were(7.49±2.02)pg/ml,(6.54±2.56)pg/ml,(4.40±1.25)pg / ml,(147.17±16.09)pg/ml.There was no statistical difference in the above indicators between the two groups(P>0.05).3.Serum hs-CRP,TNF-?,IL-6 and Lp-PLA2 levels in the experimental group after treatment were(10.99±5.03)mg/l,(5.53±2.19)pg/ml,(4.01±1.64)pg/ml,(204.92±94.05)ng/ml;the control group was(13.75±7.17)mg/l,(7.33±4.21)pg/ml,(5.19±2.12)pg/ml,(240.45±105.22)ng/ml.Comparing between groups,the levels of the above serum inflammatory factors in the experimental group were lower than those in the control group after treatment,and the differences were statistically significant(P<0.05).In ACS subgroup.After treatment,the serum hs-CRP,TNF-?,IL-6 and Lp-PLA2 levels in the experimental group were(14.93±8.88)mg/l,(6.71±3.32).pg/ml,(4.86±1.79)pg/ml,(281.20±95.53)ng/ml;the control group was(19.79±10.75)mg/l,(9.13±4.64)pg/ml,(6.41±1.90)pg/ml,(331.16±101.85)ng/ml.Compared between the two groups,after treatment,the serum inflammatory factor levels in the experimental group were lower than those in the control group,and the differences were statistically significant(P<0.05).In SA subgroup.After treatment,the serum hs-CRP,TNF-?,IL-6,and Lp-PLA2 levels in the experimental group were(5.22±1.17)mg/l,(4.02±1.45)pg/ml,(3.06±0.68)pg/ml,(111.04±18.80)ng/ml;the control group was(5.97±1.52)mg/l,(5.10±2.07)pg/ml,(3.68±1.22)pg/ml,(128.55±13.88)ng/ml.Compared between the two groups,after treatment,the serum inflammatory factor levels in the experimental group were lower than those in the control group and the differences were statistically significant(P<0.05).4.Serum hs-CRP,TNF-?,IL-6 and Lp-PLA2 levels(the specific values? have been listed above)in the experimental group were significantly lower than before treatment(the specific values have been listed above)(P<0.01);serum hs-CRP,TNF-?,IL-6 and Lp-PLA2 levels were significantly lower than before treatment(P<0.01).In ACS subgroup,the levels of the above serum inflammatory factors in the experimental group were significantly lower than those before treatment(P<0.01);the levels of the above serum inflammatory factors in the control group were significantly lower than those before treatment(P<0.01).In SA subgroup,the serum serum inflammatory factor levels in the experimental group were significantly lower than those before treatment(P<0.01);the levels of the above serum inflammatory factors in the control group were significantly lower than those before treatment(P<0.01).Conclusion: Fastigial nucleus stimulation combined with standardized coronary heart disease medication can effectively reduce the level of serum inflammatory factors in patients with coronary heart disease and reduce the inflammatory response of blood vessels.Clinical Trial Registration: URL: http://www.clinicaltrials.gov.Unique identifier: NCT04121715.